CHRS - Coherus BioSciences - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

CHRS is currently covered by 9 analysts with an average price target of $9.77. This is a potential upside of $8.77 (877%) from yesterday's end of day stock price of $1.

Coherus BioSciences's activity chart (see below) currently has 95 price targets and 91 ratings on display. The stock rating distribution of CHRS is 86.21% BUY and 13.79% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 10.58% with an average time for these price targets to be met of 79.69 days.

Highest price target for CHRS is $7, Lowest price target is $1.05, average price target is $7.84.

Most recent stock forecast was given by DOUGLAS TSAO from HC WAINWRIGHT on 29-Apr-2025. First documented stock forecast 27-Jul-2016.

Currently out of the existing stock ratings of CHRS, 25 are a BUY (86.21%), 4 are a HOLD (13.79%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$7

$5.96 (573.08%)

$7

3 months 15 days ago
(29-Apr-2025)

0/16 (0%)

$6 (600.00%)

Hold

$1.05

$0.01 (0.96%)

$1.5

3 months 20 days ago
(24-Apr-2025)

2/4 (50%)

$0.04 (3.96%)

58

Buy

$7

$5.96 (573.08%)

$7

1 years 3 months ago
(13-May-2024)

0/5 (0%)

$4.91 (234.93%)

Buy

$11

$9.96 (957.69%)

1 years 4 months 24 days ago
(20-Mar-2024)

0/4 (0%)

$8.52 (343.55%)

Hold

$22

1 years 9 months 5 days ago
(08-Nov-2023)

3/8 (37.5%)

$7.72 (54.06%)

181

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CHRS (Coherus BioSciences) average time for price targets to be met?

On average it took 79.69 days on average for the stock forecasts to be realized with a an average price target met ratio 10.58

Which analyst has the current highest performing score on CHRS (Coherus BioSciences) with a proven track record?

JASON MCCARTHY

Which analyst has the most public recommendations on CHRS (Coherus BioSciences)?

Jason Mccarthy works at MAXIM GROUP and has 2 price targets and 2 ratings on CHRS

Which analyst is the currently most bullish on CHRS (Coherus BioSciences)?

Michael Ulz with highest potential upside - $28.96

Which analyst is the currently most reserved on CHRS (Coherus BioSciences)?

Jason Mccarthy with lowest potential downside - -$0

Coherus BioSciences in the News

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 – – Q2 2025 ending cash, cash equivalents and marketable securities of $238 million – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., Aug....

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) — Coherus Oncology, Inc. (Coherus, Coherus Oncology or the Company, Nasdaq: CHRS), today announced that its second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025. Starting at 5:00 p.m. EDT on August 7, 2025, Coherus’ management team will host a conference...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?